Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;32(6):e13097.
doi: 10.1111/dth.13097. Epub 2019 Oct 17.

Long-term therapy of multiple basal cell carcinomas: Clinicodermoscopic score for monitoring of intermittent vismodegib treatment

Linda Tognetti  1 , Elisa Cinotti  1 , Diletta Fiorani  1 , Caroline Couzan  2 , Camilla Cavarretta  1 , Marie Chazelle  2 , Bruno Labeille  2 , Elisa Pianigiani  1 , Gabriele Cevenini  2 , Jean L Perrot  2 , Pietro Rubegni  1
Affiliations

Long-term therapy of multiple basal cell carcinomas: Clinicodermoscopic score for monitoring of intermittent vismodegib treatment

Linda Tognetti et al. Dermatol Ther. 2019 Nov.

Abstract

Vismodegib treatment of multiple basal cell carcinomas (BCCs) is limited by adverse effects and high relapse rates: intermittent regimens are therefore preferred for long-term administration. The objective of this study was to investigate clinical and dermoscopic changes in BCCs during long-term intermittent treatment and to identify those most indicative of tumor persistence/clearing. Clinical and dermoscopic images (n = 380 each) of 38 BCCs were acquired at 10 observation times (t0-t9). Biopsies were performed at baseline (t0) and after 72 weeks of treatment (t9). All images were evaluated retrospectively by experts who assessed the presence/absence of 12 clinical and 14 dermoscopic features: clinical scores (CScs) and dermoscopic scores (DScs) were then calculated.

Keywords: basal cell carcinoma; dermoscopy; long-term vismodegib treatment.

PubMed Disclaimer

References

REFERENCES

    1. Alarcon, I., Pasquali, P., Malvehy, J., & Puig, S. (2017). Tumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: In vivo assessment with reflectance confocal microscopy. Skin Research and Technology, 23, 283-288.
    1. Apalla, Z., Lallas, A., Tzellos, T., Sidiropoulos, T., Lefaki, I., Trakatelli, M., … Ioannides, D. (2014). Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. The British Journal of Dermatology, 170(4), 809-815.
    1. Bichakjian, C. K., Olencki T, Aasi SZ, et al. (2016). Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network, 14, 574-597.
    1. Chang, A. L., & Oro, A. E. (2012). Initial assessment of tumor regrowth after Vismodegib in advanced basal cell carcinoma. Archives of Dermatology, 148(11), 1324-1325.
    1. Couzan, C., Cinotti E., Labeille B, et al. (2018). Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after Vismodegib treatment. Journal of the European Academy of Dermatology and Venereology, 32, 763-767.

Supplementary concepts